Trials / Terminated
TerminatedNCT00449813
The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms (BY1023/NL511)
The CONQUEST-Study. Evaluation of Clinical Endpoints for Treatment-induced Changes in GERD-related Symptoms
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to compare two different endpoint measures: heartburn as assessed by the physicians versus gastroesophageal reflux disease (GERD)-related symptoms as assessed by the patient using the ReQuest™ questionnaire. The assessment is made in GERD-patients treated with a daily dose of 40 mg oral pantoprazole over an 8-week period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pantoprazole | 40 mg Pantoprazole |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2007-10-01
- Completion
- 2008-11-01
- First posted
- 2007-03-21
- Last updated
- 2012-05-07
Locations
15 sites across 2 countries: Netherlands, Switzerland
Source: ClinicalTrials.gov record NCT00449813. Inclusion in this directory is not an endorsement.